Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Pacira BioSciences Inc (NASDAQ: PCRX) was $22.93 for the day, down -2.55% from the previous closing price of $23.53. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 0.67 million shares were traded. PCRX stock price reached its highest trading level at $23.85 during the session, while it also had its lowest trading level at $22.79.
Ratios:
Our analysis of PCRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.94. For the most recent quarter (mrq), Quick Ratio is recorded 3.78 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.57.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $27.
Truist Upgraded its Hold to Buy on July 25, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 ’26 when RIKER LAUREN sold 1,416 shares for $24.24 per share. The transaction valued at 34,324 led to the insider holds 59,064 shares of the business.
RIKER LAUREN bought 1,416 shares of PCRX for $34,324 on Jan 05 ’26. On Dec 09 ’25, another insider, Cross Shawn, who serves as the Chief Financial Officer of the company, sold 15,896 shares for $25.03 each. As a result, the insider received 397,877 and left with 56,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 986477888 and an Enterprise Value of 1165451776. As of this moment, Pacira’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.40, and their Forward P/E ratio for the next fiscal year is 6.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.06. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.38 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 1.626 whereas that against EBITDA is 7.74.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.24, which has changed by 0.14501214 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $27.64, while it has fallen to a 52-week low of $19.81. The 50-Day Moving Average of the stock is -5.75%, while the 200-Day Moving Average is calculated to be -6.50%.
Shares Statistics:
PCRX traded an average of 773.84K shares per day over the past three months and 860460 shares per day over the past ten days. A total of 42.97M shares are outstanding, with a floating share count of 41.59M. Insiders hold about 3.33% of the company’s shares, while institutions hold 114.71% stake in the company. Shares short for PCRX as of 1767139200 were 7357458 with a Short Ratio of 9.51, compared to 1764288000 on 7220261. Therefore, it implies a Short% of Shares Outstanding of 7357458 and a Short% of Float of 26.76.
Earnings Estimates
Pacira BioSciences Inc (PCRX) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.73, with high estimates of $0.85 and low estimates of $0.62.
Analysts are recommending an EPS of between $3.05 and $2.87 for the fiscal current year, implying an average EPS of $2.95. EPS for the following year is $3.41, with 7.0 analysts recommending between $3.84 and $3.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $203.2M to a low estimate of $201M. As of. The current estimate, Pacira BioSciences Inc’s year-ago sales were $187.25MFor the next quarter, 4 analysts are estimating revenue of $186.54M. There is a high estimate of $188.03M for the next quarter, whereas the lowest estimate is $183.69M.
A total of 4 analysts have provided revenue estimates for PCRX’s current fiscal year. The highest revenue estimate was $732.7M, while the lowest revenue estimate was $730.92M, resulting in an average revenue estimate of $731.56M. In the same quarter a year ago, actual revenue was $700.97MBased on 6 analysts’ estimates, the company’s revenue will be $792.23M in the next fiscal year. The high estimate is $808.1M and the low estimate is $774.76M.
